These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24855766)

  • 1. [Teriflunomide (Aubagio). New treatment for multiple sclerosis].
    Sabourin G
    Perspect Infirm; 2014; 11(3):56. PubMed ID: 24855766
    [No Abstract]   [Full Text] [Related]  

  • 2. [Teriflunomide (Aubagio), oral administration].
    J Pharm Belg; 2015 Sep; (3):49-55. PubMed ID: 26513836
    [No Abstract]   [Full Text] [Related]  

  • 3. Teriflunomide (Aubagio®) for the treatment of multiple sclerosis.
    Bar-Or A
    Exp Neurol; 2014 Dec; 262 Pt A():57-65. PubMed ID: 24925677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spotlight on teriflunomide.
    Tallantyre E; Evangelou N; Constantinescu CS
    Int MS J; 2008 Jun; 15(2):62-8. PubMed ID: 18782502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aclidinium bromide, tofacitinib citrate, and teriflunomide.
    Hussar DA; Hurrey NJ
    J Am Pharm Assoc (2003); 2013; 53(1):106-10. PubMed ID: 23636164
    [No Abstract]   [Full Text] [Related]  

  • 6. [Immunomodulation with oral dosage forms and their mechanisms of action].
    Gold R
    Drug Res (Stuttg); 2013 Nov; 63 Suppl 1():S9. PubMed ID: 24242042
    [No Abstract]   [Full Text] [Related]  

  • 7. Teriflunomide and its mechanism of action in multiple sclerosis.
    Bar-Or A; Pachner A; Menguy-Vacheron F; Kaplan J; Wiendl H
    Drugs; 2014 Apr; 74(6):659-74. PubMed ID: 24740824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and trials of clinically isolated syndrome.
    Montalban X; Sastre-Garriga J
    Lancet Neurol; 2014 Oct; 13(10):962-3. PubMed ID: 25192850
    [No Abstract]   [Full Text] [Related]  

  • 9. Teriflunomide for the treatment of relapsing-remitting multiple sclerosis.
    Miller AE
    Expert Rev Clin Immunol; 2015 Feb; 11(2):181-94. PubMed ID: 25511008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teriflunomide for the treatment of multiple sclerosis.
    Oh J; O'Connor PW
    Semin Neurol; 2013 Feb; 33(1):45-55. PubMed ID: 23709212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Alemtuzumab and teriflunomide approved].
    Fischer S
    Med Monatsschr Pharm; 2013 Oct; 36(10):393-4. PubMed ID: 24266250
    [No Abstract]   [Full Text] [Related]  

  • 12. ▼Teriflunomide for multiple sclerosis.
    Drug Ther Bull; 2014 Jul; 52(7):81-4. PubMed ID: 25012149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teriflunomide for the treatment of multiple sclerosis.
    Warnke C; Stüve O; Kieseier BC
    Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S90-4. PubMed ID: 24321165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PML in a person with multiple sclerosis: Is teriflunomide the felon?
    Lorefice L; Fenu G; Gerevini S; Frau J; Coghe G; Barracciu MA; Contu F; Marrosu MG; Cocco E
    Neurology; 2018 Jan; 90(2):83-85. PubMed ID: 29212829
    [No Abstract]   [Full Text] [Related]  

  • 15. [TERIFLUNOMIDE: A NEW ORAL IMMUNOMODULATING AGENT FOR MULTIPLE SCLEROSIS].
    Bencsik K; Rózsa C; Vécsei L
    Ideggyogy Sz; 2015 Mar; 68(3-4):79-87. PubMed ID: 26434194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rebound syndrome after teriflunomide cessation in a patient with multiple sclerosis.
    Yamout BI; Said M; Hannoun S; Zeineddine M; Massouh J; Khoury SJ
    J Neurol Sci; 2017 Sep; 380():79-81. PubMed ID: 28870594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New drugs for relapsing multiple sclerosis.
    Med Lett Drugs Ther; 2012 Nov; 54(1403):89-91. PubMed ID: 23183318
    [No Abstract]   [Full Text] [Related]  

  • 18. "Nail loss after teriflunomide treatment: A new potential adverse event".
    Mancinelli L; Amerio P; di Ioia M; Di Tommaso V; De Luca G; Onofrj M; Lugaresi A
    Mult Scler Relat Disord; 2017 Nov; 18():170-172. PubMed ID: 29141803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases.
    Fragoso YD; Brooks JB
    Expert Rev Clin Pharmacol; 2015 May; 8(3):315-20. PubMed ID: 25712857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teriflunomide: A Review in Relapsing-Remitting Multiple Sclerosis.
    Scott LJ
    Drugs; 2019 Jun; 79(8):875-886. PubMed ID: 31098896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.